A retrospective comparison of two drug regimens RHE2/RH10 and RHZ2/RH10 in the treatment of tuberculous mediastinal lymphadenopathy

L.P. Ormerod
{"title":"A retrospective comparison of two drug regimens RHE2/RH10 and RHZ2/RH10 in the treatment of tuberculous mediastinal lymphadenopathy","authors":"L.P. Ormerod","doi":"10.1016/0007-0971(88)90068-X","DOIUrl":null,"url":null,"abstract":"<div><p>A retrospective radiographic comparison of two regimens, RHE2/RH10 (<em>n</em>=32) and RHZ2/RH10 (<em>n</em>=37), used in the treatment of tuberculous mediastinal lymphadenopathy is reported. The two groups did not differ in age, pretreatment or post-treatment values. The rate of improvement in serial radiographs was compared between the two groups, each patient acting as his own control. There was no difference in the incidence of initial gland enlargement at 1 month, but at 2 months RHZ2/RH10 had less enlargement (0.05&gt;<em>P</em>&gt;0.01). The rate of improvement was faster in the RHZ2/RH10 group from 2–7 months' treatment, being significantly better than RHE2/RH10 at 2 (<em>P</em>=0.003), 5 (0.01&gt;<em>P</em>) and 7 months (0.02&gt;<em>P</em>). Pyrazinamide (25–40 mg/kg) appears to be superior to ethambutol 15 mg/kg for the initial 2 months of treatment of tuberculous mediastinal lymphadenopathy. The findings may be applicable to peripheral tuberculous lymphadenopathy.</p></div>","PeriodicalId":75618,"journal":{"name":"British journal of diseases of the chest","volume":"82 ","pages":"Pages 274-281"},"PeriodicalIF":0.0000,"publicationDate":"1988-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0007-0971(88)90068-X","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British journal of diseases of the chest","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/000709718890068X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 4

Abstract

A retrospective radiographic comparison of two regimens, RHE2/RH10 (n=32) and RHZ2/RH10 (n=37), used in the treatment of tuberculous mediastinal lymphadenopathy is reported. The two groups did not differ in age, pretreatment or post-treatment values. The rate of improvement in serial radiographs was compared between the two groups, each patient acting as his own control. There was no difference in the incidence of initial gland enlargement at 1 month, but at 2 months RHZ2/RH10 had less enlargement (0.05>P>0.01). The rate of improvement was faster in the RHZ2/RH10 group from 2–7 months' treatment, being significantly better than RHE2/RH10 at 2 (P=0.003), 5 (0.01>P) and 7 months (0.02>P). Pyrazinamide (25–40 mg/kg) appears to be superior to ethambutol 15 mg/kg for the initial 2 months of treatment of tuberculous mediastinal lymphadenopathy. The findings may be applicable to peripheral tuberculous lymphadenopathy.

两种药物方案RHE2/RH10和RHZ2/RH10治疗结核性纵隔淋巴结病的回顾性比较
回顾性比较两种方案,RHE2/RH10 (n=32)和RHZ2/RH10 (n=37),用于治疗结核性纵隔淋巴结病报道。两组在年龄、治疗前后的价值上没有差异。比较两组患者连续x线片的改善率,每个患者作为自己的对照。两组在1个月时初始腺体肿大的发生率无差异,但在2个月时RHZ2/RH10的肿大较少(0.05>P>0.01)。治疗2 ~ 7个月时,RHZ2/RH10组改善速度较快,治疗2个月(P=0.003)、5个月(0.01>P)和7个月(0.02>P)时均显著优于RHE2/RH10组。在治疗结核性纵隔淋巴结病的最初2个月,吡嗪酰胺(25-40 mg/kg)似乎优于乙胺丁醇(15 mg/kg)。这些结果可能适用于周围性结核性淋巴结病。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信